Loading patent…
AssigneeVanderbilt University
InventorsWei K. Wu, Matthew Bacchetta, Sophoclis Alexopoulos, John W. Stokes, Rei Ukita, Yatrik J. Patel
Estimating the term…
A system for maintaining immune separation between an extracorporeal organ and a bioreactor includes an organ chamber holding an extracorporeal organ and a cross-circulation circuit connecting the extracorporeal organ with the bioreactor. The cross-circulation circuit can direct the flow of perfusate therebetween. The bioreactor may include an allogeneic or xenogeneic host organism. for example a swine host. The cross-circulation circuit comprises at least one semipermeable membrane configured to establish an immunologic barrier to maintain separation between the immune responses of the bioreactor and the extracorporeal organ and to maintain physiologic stability of the bioreactor and the extracorporeal organ. The immune-reduced cross-circulation circuit may improve extracorporeal organ viability for research and transplant purposes.
A system comprising:
The system of 2, wherein the host organism is allogeneic or xenogeneic to the extracorporeal organ.
The system of 5, wherein the immune compromising compounds comprise inflammatory molecules, antibodies, and immune effector cells.
The system of 5 wherein the at least one semipermeable membrane comprises a plurality of pores configured to permit non-immune compromising compounds to pass through the cross-circulation circuit based on sizes of the plurality of pores.
The system of 5, wherein the non-immune compromising compounds comprise electrolytes, hormones, substrates, and small proteins.
The system of 1, wherein the extracorporeal organ is at least one of a liver, a lung, a kidney, a heart, a limb, skin, or a tissue substrate.
The system of 1, wherein the immune response is an innate immune response or an adaptive immune response.
A cross-circulation circuit comprising:
The cross-circulation circuit of 11, wherein at least one of blood, a non-blood oxygen carrier, an acellular solution, and a crystalloid solution flows through at least one of the H loop, the O loop, and the immune separation loop.
The cross-circulation circuit of 11, wherein the H loop, the O loop, and the immune separation loop each comprise a different perfusate.
The cross-circulation circuit of 11, wherein the first membrane and the second membrane are configured to prevent immune compromising components from flowing through the first interface and/or the second interface.
The cross-circulation circuit of 14, wherein the immune compromising components comprise inflammatory molecules, antibodies, and immune effector cells.
The system of 11, wherein the first semipermeable membrane and the second semipermeable membrane each comprise a plurality of pores configured to permit non-immune comprising compounds in the perfusate to pass through based on sizes of the plurality of pores.
The system of 16, wherein the non-immune compromising compounds comprise electrolytes, hormones, substrates, and small proteins.
The cross-circulation circuit of 11, wherein the bioreactor comprises a host organism of a different species than the extracorporeal organ and the immune separation loop provides an immunologic barrier between the host organism and the extracorporeal organ to prevent xeno-immune injury of the extracorporeal organ.
A method comprising:
The method of 19, wherein the first membrane and the second membrane are configured to prevent immune compromising components from flowing through.
The method of 21, wherein the immune compromising compounds comprise inflammatory molecules, antibodies, and immune effector cells.
The method of 19, wherein the first semipermeable membrane and the second semipermeable membrane comprises a plurality of pores configured to permit non-immune compromising compounds to pass through based on sizes of the plurality of pores.
The method of 23, wherein the non-immune compromising compounds comprise electrolytes, hormones, substrates, and small proteins.
Dependencies are inferred from the claim text.